CARTIA
Adenomatous Polyp of Colon
Lewai Sharki Abdulaziz, MSc PhDSmall moleculeEarly Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Adenomatous Polyp of Colon cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Selenium University of Arizona | Phase 3 | B |
Eicosapentanoic Acid Vanderbilt University | Phase 2 | B |
Docosahexaenoic Acid Vanderbilt University | Phase 2 | B |
Acetylsalicylic Acid University of Calgary | Phase 2 | CCC |
TRIBENOSIDE Lewai Sharki Abdulaziz, MSc PhD | Early Phase 1 | CC |
LIDOCAINE Lewai Sharki Abdulaziz, MSc PhD | Early Phase 1 | CC |
Glyceryl Trinitrate Lewai Sharki Abdulaziz, MSc PhD | Early Phase 1 | CC |
Dordaviprone National Cancer Institute (NCI) | Phase 1 | C |
Same molecule, other indications
CARTIA is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →